BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, March 19, 2026
Home » Newsletters » BioWorld MedTech

BioWorld MedTech

Sep. 15, 2020

View Archived Issues
4-2-Outset-Medical-tablo.png

Outset Medical posts hefty $242M IPO

Portable dialysis machine manufacturer Outset Medical Inc. saw its shares soar after the opening of its Nasdaq IPO. The stock rose as high as $61.60 before closing at $60.68, finishing the day with a market cap of nearly $2.5 billion. Trading under the ticker symbol OM, the company priced 8.95 million of its shares at $27 apiece, upsizing its previously reported plans to offer 7.6 million shares between $22 and $24. The offering is set to close Sept. 17. Read More
deal-handshake2

Intersect ENT snags Fiagon for €60M

Sinusitis implant company Intersect ENT Inc. has agreed to acquire Fiagon AB Medical Technologies, a manufacturer of electromagnetic surgical navigation systems, for €60 million (US$71.1 million). Under the terms of the agreement, Intersect ENT will pay €15 million at the time of the closing and €15 million annually for the ensuing three years. Read More
SARS-CoV-2, neutralizing antibody diagram

Siemens Healthineers leads effort to define COVID-19 immunity with CDC, JRC

Siemens Healthineers AG snagged a key role in the mystery playing out across the world's pandemic stage – what do antibody test results mean in terms of immunity to SARS-CoV-2 and how do different tests assessing different proteins compare? The U.S. CDC and the Joint Research Centre (JRC) of the European Commission tapped the Erlanger, Germany-based company to take the lead in developing a process to standardize antibody assays. Read More
Boston-Scientific-WATCHMAN-12-5.png

Registry played a role in Watchman experience, but approval for device iteration still aspirational

The U.S. FDA has been easing gently down the road of real-world evidence (RWE) in regulatory decision-making, and the case of the Watchman left atrial appendage device is instructive in this regard. Robert Shipley, of Boston Scientific Corp. (BSX), said on webinar hosted by the Advanced Medical Technology Association that the FDA changed gears and agreed to a registry for a post-approval study for the first generation Watchman, but added that the use of registry data and other RWE for approval of a next-generation device is as yet more aspirational than practicable. Read More
U.S. vaccine illustration

U.S. vaccine plan can’t be just about COVID-19

What’s the plan? The U.S. CDC is being asked that question a lot these days – not just about COVID-19, but also about preparing for what could be a tough influenza season as flu bugs circulate with the coronavirus. Read More

Plus Therapeutics’ Rhenium Nanoliposomes are fast tracked in glioblastoma

The FDA has granted Plus Therapeutics Inc. fast track designation for its lead candidate, Rhenium Nanoliposomes (RNL), for treating recurrent glioblastoma, propelling it into the sixth cohort of a phase I dose-finding trial. Read More
Dollar-arrow-up.png

Record financings place med tech at a four-year high

Raising more money in the first three quarters of 2020 than in each of the last three full years, the med-tech industry is mirroring that of the biopharma industry, showing an unprecedented amount of financing during what is arguably the most economically disruptive pandemic in a lifetime. Read More

Appointments and advancements for Sept. 15, 2020

New hires and promotions in the med-tech industry, including: Apiject, Clearpoint Neuro, Element Science, Experity, Microbix, Orthofix, Prolucent, Rapid Micro Biosystems, Satellite Healthcare, Varian. Read More

Financings for Sept. 15, 2020

Med-tech firms raising money in public or private financings, including: Ansa Biotechnologies, Hologic, Medigate, Rejoni, Spine Align. Read More

In the clinic for Sept. 15, 2020

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Biosig, Icad, Immunexpress. Read More

Other news to note for Sept. 15, 2020

Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Anpac Bio-Medical Science, Apple, Bostongene, Cardiacsense, Chest Foundation, Concept Medical, Controlrad, Fujifilm Sonosite, Genetic Technologies, Global Plasma Solutions, Illumina, Movendo, Nihon Kohden, Palisade, Polyganics, Sherlock Biosciences, Ursa Health, Visage, Welldoc. Read More

Regulatory actions for Sept. 15, 2020

Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Cerapedics, Controlrad, Eurobio Scientific, Fibralign, GE Healthcare, Genmark Diagnostics. Read More

Regulatory front for Sept. 15, 2020

The latest global regulatory news, changes and updates affecting medical devices and technologies, including: Bayer, Neovasc. Read More

BioWorld MedTech’s Oncology Extra for Sept. 15, 2020

Keeping you up to date on recent developments in oncology, including: New algorithm prioritizes breast cancer patients for surgery, chemotherapy; Oxygen grows tumors but shrinks metastasis chances; ‘Fight or flight’ nervous system helps fight tumors, too; Proton beam therapy available in South Florida. Read More

Popular Stories

  • Today's news in brief

    BioWorld

    BioWorld briefs for March 19, 2026.

  • Art concept for targeting the brain

    Precision psychiatry beyond, or before, biomarkers

    BioWorld
    There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
  • Illustration of a motor neuron

    Keros reports beneficial effects of RKER-065 in ALS model

    BioWorld Science
    Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for March 17, 2026
  • First-in-class POLG activator restores mtDNA across mutations

    BioWorld Science
    Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing